TrialInternational journal of hematology2024

A phase 2, open-label study of ibrutinib plus rituximab in Japanese patients with Waldenstrom's macroglobulinemia.

Koji Izutsu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.